OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Lisa LeCointe-Cephas, SVP, chief ethics and compliance officer and office of general counsel, human health, Merck, uses her unique style of leadership—stop, drop, and roll—while elevating voices that need to be heard.
Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Check out the latest issue of Pharmaceutical Executive!
September 22, 2023
Project to focus on improving access to EstroGel.
The drug, 9MW3011, is also approved for clinical study by NMPA.
Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.
The blockbuster drug has previously been approved to treat multiple heart and diabetes-related conditions.
September 21, 2023
Deal to focus on development and commercialization in key emerging countries.
Medicine indicated for patients aged 12 and older.
Celexor Bio expected to focus on ell depletion of pathologic cells in autoimmune and inflammatory disorders.
September 20, 2023
Agency cites a need for more research to be completed.
Deal aims to provide diabetes treatment to patients across the continent.
Acquisition offers 300 new employees and a bigger product portfolio.